Opportunities to improve clinical care in HIV disease: Designing an effective antiretroviral drug regimen for your patient: Proceedings of a Satellite Symposium Preceding the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy Thursday, September 26, 2002 San Diego Convention Center San Diego, California: Introduction

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue SUPPL. 1, 2003, Pages

  Powderly, William G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONFERENCE PAPER; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CLINICAL PROTOCOLS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PATIENT CARE PLANNING;

EID: 0038078798     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (6)

1. Delta Coordinating Committee. Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
3. UNAIDS - HIV/AIDS documentation. Available at: http://www.unaids.org/hivaidsinfo/documents.html. Accessed March 6, 2003.
4. Valdiserri RO. Preventing new HIV infections in the US: what can we hope to achieve [abstract 4]. Presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 10-14, 2003.
5. Murphy R, Pokrovsky V, Rosenbaum, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or ATV: 108-week results of BMS study 088/044 [abstract 555]. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003.
6. Arasteh K, Clumeck N, Pozniak A, et al. First clinical results on antiretroviral activity. Pharmacokinetics, and safety of TMC114, an HIV-1 protease inhibitor, in multiple P-experienced patients [abstract 8]. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003.